ADCs containing GPC3 or CD24 antibodies may provide a more accurate and effective way of treating liver cancer, especially when systemic therapy is combined with locoregional trans-arterial administration directly into the vicinity of the HCC. The gene discussed is CD24; the disease is liver cancer.